ArticleJCO precision oncology2026
Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment.
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
purposePancreatic ductal adenocarcinoma (PDAC) ranks third in cancer-related deaths. Although national guidelines recommend germline multigene panel testing (MGPT) for all patients with PDAC, only 6%-19% undergo testing, mostly due to under-referral and genetic counselor shortages. We evaluated a coordinator-led and digitally supported workflow designed to increase access to pretest education, improve MGPT uptake, and reduce turnaround time (TAT) for patients newly diagnosed with PDAC at our center.
methodsThrough the Genetic Information for Treatment Decisions (GIFTD) Initiative, a Genetic Risk Education Coordinator (GREC) served as a liaison between providers, genetic counselors, and patients. Subsequently, we partnered with Nest Genomics to develop the GIFTD Partially Automated Nest Copilot (G-PANC), a digital tool that collects cancer history, delivers genetic education, and assesses MGPT interest before coordinator follow-up. Outcomes included genetic education completion, MGPT uptake, and TAT across sequential phases (baseline, GREC-only, and G-PANC [GREC+ Nest Copilot]).
resultsOver 1 year, 354 patients with PDAC were invited to access G-PANC; 73% activated accounts, 80% completed education, and 63% expressed MGPT interest. Among those completing education, 86% engaged with the GREC, and 81% consented to testing, including 15 initially uninterested patients. Of the 127 patients tested, 13% had pathogenic variants. Compared with a baseline/traditional workflow, the GREC-only phase was associated with increased MGPT uptake (43% to 80%) and reduced TAT (54 to 30 days). During the subsequent G-PANC phase, testing uptake remained high (77%) and TAT further decreased to 22 days.
conclusionA coordinator-led workflow substantially increased MGPT uptake and reduced TAT. Digital education integration was feasible, maintained high testing rates, and reduced TAT. Prospective evaluation will clarify the independent contributions of digital automation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.